Modality
siRNA
MOA
CAR-T CD19
Target
VEGF
Pathway
NF-κB
NB
Development Pipeline
Preclinical
~Aug 2022
→ ~Nov 2023
Phase 1
Feb 2024
→ Dec 2027
Phase 1Current
NCT03843740
923 pts·NB
2024-02→2027-12·Recruiting
923 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-12-271.7y awayInterim· NB
Trial Timeline
Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P1
Recruit…
Catalysts
Interim
2027-12-27 · 1.7y away
NB
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03843740 | Phase 1 | NB | Recruiting | 923 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-1546 | Roche | Phase 2/3 | C5 | |
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| Datoglumide | AbbVie | Approved | CFTR | |
| TAK-8730 | Takeda | Phase 2 | VEGF | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF | |
| GIL-2259 | Gilead Sciences | Approved | SMN2 | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| BII-4342 | Biogen | Phase 2/3 | CGRP | |
| Pemicapivasertib | Legend Biotech | Phase 3 | VEGF | |
| Sematapinarof | Legend Biotech | NDA/BLA | VEGF |